Developer docs
API playgroundTry for free, no card

Search company profiles

BrainWaveBank

Full company profile

uuid0002n1n

Namestring
BrainWaveBank
Legal namestring
Cumulus Neuroscience Limited
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Cumulus Neuroscience Limited, headquartered in Belfast with a second office in Dublin, operates the NeuLogiq® Platform, a multi-modal digital assessment and neurophysiological monitoring system designed for use in central nervous system (CNS) clinical trials. The platform combines digitized cognitive assessments with brain function data capture to enable frequent, longitudinal monitoring of patients both in clinic and at home, addressing well-documented pain points in CNS drug development such as placebo response, symptom heterogeneity, subjective endpoints, and the absence of objective biomarkers. It was co-designed with a Top 10 Pharma Advisory Group comprising Biogen, Boehringer Ingelheim, BMS, GSK, J&J, Lilly, MSD, Pfizer, Roche, and Takeda, lending clinical and commercial credibility from inception.

The company generates revenue through enterprise clinical trial services, providing platform access, data collection, and study support to pharmaceutical sponsors on what the source describes as a subscription or recurring engagement basis. Pricing is not publicly disclosed and is contact-based, consistent with bespoke enterprise contracts. The go-to-market motion is direct enterprise field sales — the company runs a 'Book a Demo' CTA and attends conferences such as AAIC — targeting translational and clinical operations buyers inside top-tier pharma. Funding has totaled approximately $16.4 million across nine equity and grant tranches from 2016 through 2020, sourced from a mix of regional venture funds (Par Equity, Clarendon, Whiterock, TechStart Ventures, ACF Investors, KX), UK life sciences investors (LifeArc), government programs (Innovate UK, Invest Northern Ireland), and the UK Future Fund. The current operating status is active, but post-2020 momentum cannot be confirmed from the available data.

Leadership comprises founder-CEO Ronan Cunningham, founder and CSO Brian Murphy, chairman Des Speed, and Professor Ian Robertson (Trinity College Dublin) as chair of the science advisory board, signaling deep neuroscience and academic ties.

Short descriptiontext

Cumulus Neuroscience operates the NeuLogiq Platform, a multi-modal digital and neurophysiological assessment system for in-clinic and at-home brain function monitoring in CNS clinical trials, serving top global pharmaceutical sponsors including a Top 10 Pharma Advisory Group.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBelfast, United Kingdom
HQ citystring
Belfast
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
brain monitoring technology, cognitive performance tracking, neurophysiological assessment, digital brain health, consumer neuroscience
Industry2 codes
PRIMARYHLACAOAA
Electronic Data Capture (EDC) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
NAICS code1 code
  • Other Scientific and Technical Consulting Services54169
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Digital CNS Clinical Trial Technology
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Clinical Trial Services
TypeSubscription Recurring
Description

Revenue generated through providing the NeuLogiq Platform for use in CNS clinical studies conducted by pharmaceutical companies. Services likely include platform access, data collection, and support for clinical trials.

cumulusneuro.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1NeuLogiq® Platform
Description

A platform providing frequent, reliable in-clinic and at-home longitudinal monitoring of discrete brain functions, designed for use in CNS clinical studies.

cumulusneuro.com
Core offering1 text field

BrainWaveBank develops digital tools that measure and track brain activity and cognitive performance for anyone, anytime, anywhere. The company provides multi-modal digital brain assessments combining neurophysiological data capture (including EEG) with digitized cognitive tests, enabling frequent, reliable in-clinic and at-home longitudinal monitoring of discrete brain functions. The technology underpins the NeuLogiq® Platform, designed in collaboration with 10 top pharmaceutical companies for use in central nervous system (CNS) clinical studies and drug development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Achieve more data per participant, enabling powering of smaller studies
+1 more record
Product overview1 text field

Cumulus Neuroscience offers a unified platform called NeuLogiq® Platform. The platform provides multi-modal assessments for use in-clinic or at home, combining digital assessments and neurophysiological data to support CNS (Central Nervous System) drug development. The NeuLogiq Platform was designed for use in CNS clinical studies in collaboration with 10 Top Pharma Companies and includes features for frequent, reliable longitudinal monitoring of discrete brain functions.

Product and service1 record
1NeuLogiq® Platform
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Top 10 pharmaceutical company collaborating on CNS clinical studies using the NeuLogiq Platform. Part of the Top 10 Pharma Advisory Group that helped design the platform for clinical relevance.

2Boehringer Ingelheim
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Top 10 pharmaceutical company collaborating on CNS clinical studies using the NeuLogiq Platform. Part of the Top 10 Pharma Advisory Group.

cumulusneuro.com
3Bristol Myers Squibb (BMS)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Top 10 pharmaceutical company collaborating on CNS clinical studies using the NeuLogiq Platform. Part of the Top 10 Pharma Advisory Group.

cumulusneuro.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Top 10 pharmaceutical company collaborating on CNS clinical studies using the NeuLogiq Platform. Part of the Top 10 Pharma Advisory Group.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Top 10 pharmaceutical company collaborating on CNS clinical studies using the NeuLogiq Platform. Part of the Top 10 Pharma Advisory Group.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Top 10 pharmaceutical company collaborating on CNS clinical studies using the NeuLogiq Platform. Part of the Top 10 Pharma Advisory Group.

7MSD
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Top 10 pharmaceutical company collaborating on CNS clinical studies using the NeuLogiq Platform. Part of the Top 10 Pharma Advisory Group.

cumulusneuro.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Top 10 pharmaceutical company collaborating on CNS clinical studies using the NeuLogiq Platform. Part of the Top 10 Pharma Advisory Group.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Top 10 pharmaceutical company collaborating on CNS clinical studies using the NeuLogiq Platform. Part of the Top 10 Pharma Advisory Group.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Top 10 pharmaceutical company collaborating on CNS clinical studies using the NeuLogiq Platform. Part of the Top 10 Pharma Advisory Group.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Provides digital cognitive assessment tools (CANTAB) for CNS clinical trials — directly comparable to Cumulus's digitized cognitive assessment capability and the same pharma customer base.

TypeDirect peer
Description

Specializes in computerized cognitive testing for clinical trials in CNS indications such as Alzheimer's, depression, and oncology — overlapping use case and customer profile to Cumulus.

TypeBroad incumbent
Description

Large clinical trial technology provider (formed from ERT, Bioclinica, and CRF Health) offering CNS/neurological endpoints, eCOA, and wearables — broader portfolio but overlapping digital CNS assessment functionality.

TypeDirect peer
Description

Wearable biosensor and continuous-monitoring platform specifically designed for clinical trials, including CNS indications — directly comparable remote-patient-monitoring value proposition to NeuLogiq.

5IXICO
TypeDirect peer
Description

UK-listed neuroimaging biomarker CRO serving CNS clinical trials in Alzheimer's, Huntington's, and other neurological indications — overlapping customer base and trial-endpoint focus.

TypeBroad incumbent
Description

Leading enterprise EDC and clinical trial platform (Rave). Although far broader, it increasingly bundles digital endpoint capture including CNS modules and is the dominant platform Cumulus must displace.

TypeBroad incumbent
Description

Cloud-based life sciences platform including Veeva Vault CTMS and clinical operations — competes at the broader enterprise clinical-trial software layer where Cumulus's pharma buyers also procure.

TypeDirect peer
Description

Wearable activity, sleep, and digital endpoint monitoring platform used in CNS and other clinical trials — overlapping remote/at-home objective measurement capability in the same pharma trials.

TypeBroad incumbent
Description

Clinical trial technology provider offering eCOA, patient-centric data capture, and CNS-focused solutions — directly competes for the same clinical-trial endpoint budgets at top pharma.

TypeEmerging player
Description

Medical-grade wearable sensors and digital biomarkers used in neurology clinical research and decentralized trials — emerging alternative for physiological data capture within CNS studies.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BrainWaveBank

Digital CNS Clinical Trial Technologybrainwavebank.com

Cumulus Neuroscience operates the NeuLogiq Platform, a multi-modal digital and neurophysiological assessment system for in-clinic and at-home brain function monitoring in CNS clinical trials, serving top global pharmaceutical sponsors including a Top 10 Pharma Advisory Group.

What BrainWaveBank does

Cumulus Neuroscience Limited, headquartered in Belfast with a second office in Dublin, operates the NeuLogiq® Platform, a multi-modal digital assessment and neurophysiological monitoring system designed for use in central nervous system (CNS) clinical trials. The platform combines digitized cognitive assessments with brain function data capture to enable frequent, longitudinal monitoring of patients both in clinic and at home, addressing well-documented pain points in CNS drug development such as placebo response, symptom heterogeneity, subjective endpoints, and the absence of objective biomarkers. It was co-designed with a Top 10 Pharma Advisory Group comprising Biogen, Boehringer Ingelheim, BMS, GSK, J&J, Lilly, MSD, Pfizer, Roche, and Takeda, lending clinical and commercial credibility from inception.

The company generates revenue through enterprise clinical trial services, providing platform access, data collection, and study support to pharmaceutical sponsors on what the source describes as a subscription or recurring engagement basis. Pricing is not publicly disclosed and is contact-based, consistent with bespoke enterprise contracts. The go-to-market motion is direct enterprise field sales — the company runs a 'Book a Demo' CTA and attends conferences such as AAIC — targeting translational and clinical operations buyers inside top-tier pharma. Funding has totaled approximately $16.4 million across nine equity and grant tranches from 2016 through 2020, sourced from a mix of regional venture funds (Par Equity, Clarendon, Whiterock, TechStart Ventures, ACF Investors, KX), UK life sciences investors (LifeArc), government programs (Innovate UK, Invest Northern Ireland), and the UK Future Fund. The current operating status is active, but post-2020 momentum cannot be confirmed from the available data.

Leadership comprises founder-CEO Ronan Cunningham, founder and CSO Brian Murphy, chairman Des Speed, and Professor Ian Robertson (Trinity College Dublin) as chair of the science advisory board, signaling deep neuroscience and academic ties.

BrainWaveBank firmographics

Firmographics
Name
BrainWaveBank
Legal name
Cumulus Neuroscience Limited
Website
https://brainwavebank.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Cumulus Neuroscience operates the NeuLogiq Platform, a multi-modal digital and neurophysiological assessment system for in-clinic and at-home brain function monitoring in CNS clinical trials, serving top global pharmaceutical sponsors including a Top 10 Pharma Advisory Group.
Ownership category
akta.pro rank

BrainWaveBank industry classification

Industry
Product category
Digital CNS Clinical Trial Technology
NAICS
Other Scientific and Technical Consulting Services (54169)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLACAOAA
Electronic Data Capture (EDC) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

Keywords

  • Brain monitoring technology
  • Cognitive performance tracking
  • Neurophysiological assessment
  • Digital brain health
  • Consumer neuroscience

Where BrainWaveBank is headquartered

Location

Headquarters

HQ city
Belfast
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

BrainWaveBank business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Clinical Trial Services: Revenue generated through providing the NeuLogiq Platform for use in CNS clinical studies conducted by pharmaceutical companies. Services likely include platform access, data collection, and support for clinical trials.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

BrainWaveBank product offering

Product offering

Core offering

BrainWaveBank develops digital tools that measure and track brain activity and cognitive performance for anyone, anytime, anywhere. The company provides multi-modal digital brain assessments combining neurophysiological data capture (including EEG) with digitized cognitive tests, enabling frequent, reliable in-clinic and at-home longitudinal monitoring of discrete brain functions. The technology underpins the NeuLogiq® Platform, designed in collaboration with 10 top pharmaceutical companies for use in central nervous system (CNS) clinical studies and drug development.

Product overview

Cumulus Neuroscience offers a unified platform called NeuLogiq® Platform. The platform provides multi-modal assessments for use in-clinic or at home, combining digital assessments and neurophysiological data to support CNS (Central Nervous System) drug development. The NeuLogiq Platform was designed for use in CNS clinical studies in collaboration with 10 Top Pharma Companies and includes features for frequent, reliable longitudinal monitoring of discrete brain functions.

Differentiator

Problem solved

Functional benefit

Brands

  • NeuLogiq® Platform: A platform providing frequent, reliable in-clinic and at-home longitudinal monitoring of discrete brain functions, designed for use in CNS clinical studies.

Products and services

  • NeuLogiq® Platform

Quantifiable outcome

  • Achieve more data per participant, enabling powering of smaller studies
  • +1 more outcomes

Companies that use BrainWaveBank

Customer profile

Named customers10 records

Segments1 record

Ideal customer profiles1 record

BrainWaveBank technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

BrainWaveBank partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core.

  • BiogencoreStrategic or Co-development PartnerTop 10 pharmaceutical company collaborating on CNS clinical studies using the NeuLogiq Platform. Part of the Top 10 Pharma Advisory Group that helped design the platform for clinical relevance.
  • Boehringer IngelheimcoreStrategic or Co-development PartnerTop 10 pharmaceutical company collaborating on CNS clinical studies using the NeuLogiq Platform. Part of the Top 10 Pharma Advisory Group.
  • Bristol Myers Squibb (BMS)coreStrategic or Co-development PartnerTop 10 pharmaceutical company collaborating on CNS clinical studies using the NeuLogiq Platform. Part of the Top 10 Pharma Advisory Group.
  • GSKcoreStrategic or Co-development PartnerTop 10 pharmaceutical company collaborating on CNS clinical studies using the NeuLogiq Platform. Part of the Top 10 Pharma Advisory Group.
  • Johnson & Johnson (J&J)coreStrategic or Co-development PartnerTop 10 pharmaceutical company collaborating on CNS clinical studies using the NeuLogiq Platform. Part of the Top 10 Pharma Advisory Group.
  • Eli LillycoreStrategic or Co-development PartnerTop 10 pharmaceutical company collaborating on CNS clinical studies using the NeuLogiq Platform. Part of the Top 10 Pharma Advisory Group.
  • MSDcoreStrategic or Co-development PartnerTop 10 pharmaceutical company collaborating on CNS clinical studies using the NeuLogiq Platform. Part of the Top 10 Pharma Advisory Group.
  • PfizercoreStrategic or Co-development PartnerTop 10 pharmaceutical company collaborating on CNS clinical studies using the NeuLogiq Platform. Part of the Top 10 Pharma Advisory Group.
  • RochecoreStrategic or Co-development PartnerTop 10 pharmaceutical company collaborating on CNS clinical studies using the NeuLogiq Platform. Part of the Top 10 Pharma Advisory Group.
  • TakedacoreStrategic or Co-development PartnerTop 10 pharmaceutical company collaborating on CNS clinical studies using the NeuLogiq Platform. Part of the Top 10 Pharma Advisory Group.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

BrainWaveBank competitors and assessment

Company assessment

Direct peers

  • Cambridge Cognition: Provides digital cognitive assessment tools (CANTAB) for CNS clinical trials — directly comparable to Cumulus's digitized cognitive assessment capability and the same pharma customer base.
  • Cogstate: Specializes in computerized cognitive testing for clinical trials in CNS indications such as Alzheimer's, depression, and oncology — overlapping use case and customer profile to Cumulus.
  • VivoSense: Wearable biosensor and continuous-monitoring platform specifically designed for clinical trials, including CNS indications — directly comparable remote-patient-monitoring value proposition to NeuLogiq.
  • IXICO: UK-listed neuroimaging biomarker CRO serving CNS clinical trials in Alzheimer's, Huntington's, and other neurological indications — overlapping customer base and trial-endpoint focus.
  • ActiGraph: Wearable activity, sleep, and digital endpoint monitoring platform used in CNS and other clinical trials — overlapping remote/at-home objective measurement capability in the same pharma trials.

Broad incumbents

  • Clario: Large clinical trial technology provider (formed from ERT, Bioclinica, and CRF Health) offering CNS/neurological endpoints, eCOA, and wearables — broader portfolio but overlapping digital CNS assessment functionality.
  • Medidata Solutions (Dassault Systèmes): Leading enterprise EDC and clinical trial platform (Rave). Although far broader, it increasingly bundles digital endpoint capture including CNS modules and is the dominant platform Cumulus must displace.
  • Veeva Systems: Cloud-based life sciences platform including Veeva Vault CTMS and clinical operations — competes at the broader enterprise clinical-trial software layer where Cumulus's pharma buyers also procure.
  • Signant Health: Clinical trial technology provider offering eCOA, patient-centric data capture, and CNS-focused solutions — directly competes for the same clinical-trial endpoint budgets at top pharma.

Emerging players

  • Empatica: Medical-grade wearable sensors and digital biomarkers used in neurology clinical research and decentralized trials — emerging alternative for physiological data capture within CNS studies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

BrainWaveBank social profiles

Digital presence

BrainWaveBank compliance and trust

Trust signal

Compliance1 record

BrainWaveBank financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BrainWaveBank leadership team

Management profile

Number of profiles

Profiles4 records

BrainWaveBank funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BrainWaveBank M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BrainWaveBank

What does BrainWaveBank do?

BrainWaveBank develops digital tools that measure and track brain activity and cognitive performance for anyone, anytime, anywhere. The company provides multi-modal digital brain assessments combining neurophysiological data capture (including EEG) with digitized cognitive tests, enabling frequent, reliable in-clinic and at-home longitudinal monitoring of discrete brain functions. The technology underpins the NeuLogiq® Platform, designed in collaboration with 10 top pharmaceutical companies for use in central nervous system (CNS) clinical studies and drug development.

Is BrainWaveBank a public or private company?

BrainWaveBank is a private company. It is classified as venture growth investor backed and is currently operating.

When was BrainWaveBank founded?

BrainWaveBank was founded in 2015. It employs 11 to 50 people.

Where is BrainWaveBank based?

BrainWaveBank is headquartered in Belfast, United Kingdom, in the Europe region.

How does BrainWaveBank make money?

One revenue line is on record: clinical Trial Services.

Who are BrainWaveBank's main competitors?

Direct peers on record are Cambridge Cognition, Cogstate, VivoSense, IXICO and ActiGraph. Broad incumbents are Clario, Medidata Solutions (Dassault Systèmes), Veeva Systems and Signant Health. Empatica is listed as an emerging player.

Does BrainWaveBank have an API?

No public API is recorded for BrainWaveBank.

What industry is BrainWaveBank in?

BrainWaveBank's product category is Digital CNS Clinical Trial Technology. Its primary akta.pro industry code is HLACAOAA, Electronic Data Capture (EDC) Platforms, with a secondary code of HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables). Its NAICS code is 54169 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BusinessCloudGamified in-home brain tracking tech raises £1.1mBrainWaveBank, a Belfast-based firm developing in-home brain tracking for Alzheimer's and depression, raised £1.1m led by Par Equity. The funding will develop its wireless EEG headset and gamified tests, with contracts secured from pharma and biotech firms. The company plans to scale commercial activities and enter global clinical trials.Silicon RepublicBelfast’s BrainWaveBank bags €1.2m in fundingBelfast-based BrainWaveBank raised €1.2m in funding led by Par Equity, Techstart Ventures, the Angel CoFund, and British Business Investments. The round brings total funding to €4.1m, including prior grants. The company will use the funds to develop and commercialize its wearable EEG device for measuring brain activity.The Irish TimesBrainWaveBank raises €1.2m for its ‘Fitbit for the brain’ technologyBrainWaveBank raised £1.1 million (€1.2 million) to commercialize its wireless EEG headset for cognitive fitness. The funding brings total equity investment to £3.7 million, with £2 million in grants. CEO Ronan Cunningham said the investment will accelerate platform development.PR NewswireKx Selected by BrainWaveBank as the Platform for the World's First Big Data Collection of Brainwave ActivityBrainWaveBank, an innovative start-up focused on cognitive health, has selected Kx technology—a division of global technology provider FD—to power its neuroscience platform for building the world's first Big Data collection of brainwave activity data. The platform will use AI to analyse data from a low-cost EEG headset worn while playing mobile games, enabling individuals to monitor cognitive performance and detect early signs of conditions such as Alzheimer's disease. The cognitive health assessment market is expected to reach US$8.1 billion by 2021, with early detection potentially reducing care costs by 35% or more.EU-StartupsBelfast-based BrainWaveBank secures over £1 million in funding to tackle the early detection of dementiaBrainWaveBank, a Belfast-based health-tech startup, secured over £1 million in funding from Angel CoFund, techstart NI, Innovate UK, and Invest Northern Ireland. The company's technology uses a wearable device and smartphone to track cognitive health and detect early signs of dementia. The funding will accelerate technology development and bring the product to market.FinSMEsBrainWaveBank Secures over £1M in FundingBrainWaveBank, a Belfast-based healthtech startup, raised £1m in funding from Government-backed Angel CoFund, techstart NI, Innovate UK, and Invest Northern Ireland. The company will use the funds to develop its neuroscience platform and affordable hardware for mass consumer markets, including wearables and contact sports tracking.